Node Evaluation” (page 1116) for more information on pathologic review of dissected lymph nodes. Adjuvant Therapy Localized SBAs are treated with surgical resection, but local and distant recurrences are common, and optimal perioperative therapy is
Search Results
Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology
Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi-Jen Chen, Kristen K. Ciombor, Stacey A. Cohen, Harry S. Cooper, Dustin A. Deming, Ignacio Garrido-Laguna, Jean L. Grem, Sarah E. Hoffe, Joleen Hubbard, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina S. Pedersen, Leonard B. Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Alyse Johnson-Chilla, Kristina M. Gregory, and Lisa A. Gurski
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Daniel G. Coit, John A. Thompson, Mark R. Albertini, Christopher Barker, William E. Carson III, Carlo Contreras, Gregory A. Daniels, Dominick DiMaio, Ryan C. Fields, Martin D. Fleming, Morganna Freeman, Anjela Galan, Brian Gastman, Valerie Guild, Douglas Johnson, Richard W. Joseph, Julie R. Lange, Sameer Nath, Anthony J. Olszanski, Patrick Ott, Aparna Priyanath Gupta, Merrick I. Ross, April K. Salama, Joseph Skitzki, Jeffrey Sosman, Susan M. Swetter, Kenneth K. Tanabe, Evan Wuthrick, Nicole R. McMillian, and Anita M. Engh
Adjuvant Systemic Therapy for Melanoma Brief History of Adjuvant Therapy Options for Melanoma For adjuvant treatment of melanoma in patients rendered free of disease by surgery, traditional systemic therapy approaches have proven to be ineffective
Rectal Cancer
Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Lucille A. Leong, Edward Lin, Michael G. Martin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Deborah A. Freedman-Cass, and Kristina M. Gregory
bulk (see “Neoadjuvant and Adjuvant Therapy for Resectable Nonmetastatic Disease,” page 1547); sphincter preservation may become possible in patients in whom initial tumor bulk prevented consideration of this surgery and exposure to the tumor is
Optimizing Systemic Therapy for Bladder Cancer
Sumanta K. Pal, Matthew I. Milowsky, and Elizabeth R. Plimack
receive perioperative chemotherapy, including both neoadjuvant and adjuvant therapy. 23 Although a certain proportion of patients may be poor candidates for therapy based on comorbidity or impaired renal function (thereby precluding cisplatin
Photodynamic Therapy and Antitumor Immunity
Sandra O. Gollnick
improved response when we used PDT lysate.” These vaccines seemed to inhibit the growth of both new and established tumors, suggesting their clinical potential as an adjuvant therapy. The generation of effective vaccines depends on active metabolism, at
Measuring Opportunities to Improve Timeliness of Breast Cancer Care at Dana-Farber/Brigham and Women’s Cancer Center
Craig A. Bunnell, Katya Losk, Sarah Kadish, Nancy Lin, Judith Hirshfield-Bartek, Linda Cutone, Kristen Camuso, Mehra Golshan, and Saul Weingart
. The data included the following milestones: diagnosis by needle biopsy, first definitive surgery, last definitive surgery, and adjuvant therapy timing (chemotherapy, radiation therapy, or endocrine therapy). NCCN also provided benchmarking data for the
Strategies for the Management of Early-Stage Breast Cancer in Older Women
Lee S. Schwartzberg and Sarah L. Blair
/carboplatin/trastuzumab. 5 years of tamoxifen reduced recurrences in patients aged 65 years and older. 13 “Based on these data, for the ‘younger’ older woman completing 5 years of adjuvant therapy who is at risk for recurrence, an additional 5 years of treatment is
Update on Immunotherapy for Melanoma
Antoni Ribas
. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma . J Clin Oncol 2006 ; 24 : 1188 – 1194 . 17. Spitler LE Grossbard ML Ernstoff MS . Adjuvant therapy of stage III and IV malignant
New Agents for Colorectal Cancer
Mary F. Mulcahy and Al B. Benson III
G . Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma: German Cancer Aid 17-1A Study Group . Lancet 1994 ; 343 : 1177 – 1183 . 37 Riethmuller G Holz E Schlimok G . Monoclonal
Colon Cancer
Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett
Weeks J . Controversies regarding laparoscopic colectomy for malignant diseases . Curr Opin Gen Surg 1994 : 208 – 213 . 65 Sun W Haller DG . Adjuvant therapy of colon cancer . Semin Oncol 2005 ; 32 : 95 – 102 . 66 Baddi L
